Personal Introduction

Dr. Bing Su obtained his B.S. degree from Peking University in 1984 and his Ph.D. degree from Yale University in 1991. He did his postdoctoral training with Dr. Michael Karin at the University of California San Diego before starting his academic career in 1995 as an Assistant Professor at the University of Texas M. D. Anderson Cancer Center where he was promoted to a tenured full Professor in 2006. He moved to Yale University in 2006 as a tenured faculty at the Department of Immunobiology until 2014 when he relocated to SJTU in China. Dr. Bing Su is now the Director of Shanghai Institute of Immunology and Chair of Department of Immunology and Microbiology at Shanghai JiaoTong University School of Medicine, Co-Founding Director of Shanghai JiaoTong University School of Medicine-Yale University Institute for Immune Metabolism (SYIIM) and an Adjunct Professor at Department of Immunobiology at Yale University School of Medicine. Dr. Su also holds a KC Wong Chair Professorship at Shanghai JiaoTong University

Dr. Su’s research focuses on the intracellular signal transduction pathways controlled by the mammalian target of rapamycin (mTOR) and the mitogen activated protein kinases (MAPKs). He studies the roles of these intracellular signaling cascades in immune regulation and vascular function. Dr. Su has published over 110 peer-reviewed papers, many of which were in high-impact journals such as Nature, Cell, Nature Genetics, Nature Immunology, Immunity, Molecular Cell, EMBO J, etc., with citation over 15000. His research has been supported from grants awarded by Ministry of National Scinece and Technology (Chief Scientist), as well as National Natural Science Foundation of China (NSFC) and Shanghai Science and Technology Commission.

Dr. Su is a member of Chinese Biological Investigator Society and a member of Society of Chinese Bioscientists in America (SCBA). He served on many review committees including NIH Study Sections, the Review Committee for the Key Programs of NSFC, etc.  He is also the editor-in-chief of Current Immunology, and the associate editor of Journal of Molecular Cell Biology and Current Research in Immunology.

Scientific Research Projects

• Project Number: 8258810005

• Principal Investigator: Bing Su

• Funding Source: National Natural Science Foundation of China

• Title of Project: 国家自然科学基金卓越创新群体（A类）

• Dates of Approved Project: 2026.01~2030.12

• Total Costs: ¥ 10000,000

• Project Number: 82341222

• Principal Investigator: Bing Su

• Funding Source:

• Title of Project: 靶向间质细胞治疗克罗恩病及其纤维化的策略研究(联合申请B)

• Dates of Approved Project: 2024.01~2026.12

• Total Costs: ¥ 2000,000

• Project Number: 2021YFA1301400

• Principal Investigator: Bing Su

• Funding Source: Ministry of Science and Technology of China

• Title of Project: 呼吸道病毒感染免疫应答的全景研究

• Dates of Approved Project: 2021.12~2026.11

• Total Costs: ¥ 21000,000

• Project Number: 31930035

• Principal Investigator: Bing Su

• Funding Source: National Natural Science Foundation of China

• Title of Project (Subproject): Modulation of gut immune homeostasis by innate lymphoid cells in health and diseases

• Dates of Approved Project: 2020-01~2024-12

• Total Costs: ¥ 3080,000

• Project Number: 91942311

• Principal Investigator: Bing Su

• Funding Source: Shanghai Science and Technology Committee

• Funding Source: National Natural Science Foundation of China (重大研究计划）

• Modulation of gut immune homeostasis by the novel subsets of gut stromal cells

• Dates of Approved Project: 2020-01~2022-12

• Total Costs: ¥ 2500,000

• Project Number: 20410714000

• Principal Investigator: Bing Su

• Funding Source: Shanghai Science and Technology Committee

• Title of Project (Subproject): The role of novel coronavirus protein in mediating pneumonia and cellular molecular mechanism

• Dates of Approved Project: 2020-06~2023-5

• Total Costs: ¥ 450,000

• Project Number: 32061143028

• Principal Investigator: Bing Su

• Funding Source: National Natural Science Foundation of China

• Title of Project (Subproject): Ontogeny, plasticity and function of two emerging populations of mesenchymal cells in gut homeostasis and damage repair

• Dates of Approved Project: 2020.10~2023.5

• Total Costs: ¥ 1980,000

Scientific Research Projects

1. Li J, Zhang C, Huang X, Sun H, …, Chen J, Liu Z, Ginhoux F, Chen C*, Su B*, Fang JY*. Candida albicans synergizes with Fusobacterium nucleatum in colorectal cancer progression via the Flo9-RadD interaction. Cancer Cell. 2026 Feb 26:S1535-6108(26)00100-5.

2. Ma W, Chen H, Gao F, Zhao H, Wu N, Zhang S, Zhu Y, Xu Z, Lan Y, Liu B, Ye Y, Liu Z*, Ginhoux F*, Su B*. Embryonic mast cells arise from the Cpa3-expressing precursors but not granulocyte-monocyte progenitors. Sci China Life Sci. 2025 Aug;68(8):2363-2378.

3. Zhang Y, Wang J, Sun H, Xun Z, He Z, Zhao Y, Qi J, Sun S, Yang Q, Gu Y, Zhang L, Zhou C, Ye Y, Wu N*, Zou D*, Su B*. TWIST1+FAP+ fibroblasts in the pathogenesis of intestinal fibrosis in Crohn's disease. The Journal of clinical investigation. 2024-Jul-18 2024;

4. Li S, Ouyang X, Sun H, Jin J, …, Zhong Q, Liang Y, Pierre P, Zou Q, Ye Y, Su B. DEPDC5 protects CD8+ T cells from ferroptosis by limiting mTORC1-mediated purine catabolism. Cell Discovery. May 20 2024;10(1)53.

5. Guo W, Li Z, Anagnostopoulos G, Kong WT, …, Bleriot C, Liu Z, Shen B, Venteclef N, Su B*, Ginhoux F*. Notch signaling regulates macrophage-mediated inflammation in metabolic dysfunction-associated steatotic liver disease. Immunity. Oct 8 2024;57(10):2310-2327 e6.

6. Ge MK, Zhang C, Zhang N, He P, Cai HY, …, Zhou XL, Su B*, Chen GQ*, Shen SM*. The tRNA-GCN2-FBXO22-axis-mediated mTOR ubiquitination senses amino acid insufficiency. Cell Metab. Dec 5 2023;35(12):2216-2230 e8.

7. Liu H, Li L, Hao Y, Li J, Liu Z, Qi J, Zhang J, Wu N, Wu D, Gao C, Chen L, Shen L, Cheng J, Su B. Identification of two migratory colon ILC2 populations differentially expressing IL-17A and IL-5/IL-13. Sci China Life Sci. Jan 2023;66(1):67-80.

8. Qi J, Sun H, Zhang Y, Wang Z, Xun Z, …, Han L, Ginhoux F, Liu Y, Ye Y*, Su B*. Single-cell and spatial analysis reveal interaction of FAP(+) fibroblasts and SPP1(+) macrophages in colorectal cancer. Nat Commun. Apr 1 2022;13(1):1742

9. Deng H, Xu Y, Hu X, Zhuang ZW, Chang Y, Wang Y, Ntokou A, Schwartz MA, Su B*, Simons M*. MEKK3-TGFbeta crosstalk regulates inward arterial remodeling. Proc Natl Acad Sci U S A. Dec 21 2021;118(51):e2112625118.

10. Qi J, Crinier A, Escaliere B, Ye Y, Wang Z, …, Shen L*, Narni-Mancinelli E*, Vivier E*, Su B*. Single-cell transcriptomic landscape reveals tumor specific innate lymphoid cells associated with colorectal cancer progression. Cell Rep Med. Aug 17 2021;2(8):100353.

11. Wu N, Sun H, Zhao X, Zhang Y, Tan J, Qi Y, …, Zhou B, Ng LG, Zou D, Ye Y, Flavell RA, Ginhoux F, Su B. MAP3K2-regulated intestinal stromal cells define a distinct stem cell niche. Nature. Apr 2021;592(7855):606-610.

12. Yang XD*, Li W, Zhang S, Wu D, Jiang X, Tan R, Niu X, Wang Q, Wu X, Liu Z, Chen LF, Qin J, Su B*. PLK4 deubiquitination by Spata2-CYLD suppresses NEK7-mediated NLRP3 inflammasome activation at the centrosome. EMBO J. Jan 15 2020;39(2):e102201.

13. Liu Z, Gu Y, Chakarov S, Bleriot C, Kwok I, …, Ng LG, Wang H, Liu Z, Su B*, Ginhoux F*. Fate Mapping via Ms4a3-Expression History Traces Monocyte-Derived Cells. Cell. Sep 5 2019;178(6):1509-1525 e19.

14. Li M, Lazorchak AS, Ouyang X, Zhang H, …, Jiang S, Li F, Su B. Sin1/mTORC2 regulate B cell growth and metabolism by activating mTORC1 and Myc. Cell Mol Immunol. Sep 2019;16(9):757-769.

15. Zhang F, Lazorchak AS, Liu D, Chen F, Su B. Inhibition of the mTORC2 and chaperone pathways to treat leukemia. Blood. Jun 21 2012;119(25):6080-8.

16. Chang X, Liu F, Wang X, Lin A, Zhao H, Su B. The kinases MEKK2 and MEKK3 regulate transforming growth factor-beta-mediated helper T cell differentiation. Immunity. Feb 25 2011;34(2):201-12.

17. Lazorchak AS, Liu D, Facchinetti V, Di Lorenzo A, Sessa WC, Schatz DG, Su B. Sin1-mTORC2 suppresses rag and il7r gene expression through Akt2 in B cells. Mol Cell. Aug 13 2010;39(3):433-43.

18. Facchinetti V, Ouyang W, Wei H, Soto N, …, Qin J, Zhang P, Su B*, Jacinto E*. The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C. EMBO J. Jul 23 2008;27(14):1932-43.

19. Jacinto E, Facchinetti V, Liu D, Soto N, Wei S, Jung SY, Huang Q, Qin J, Su B. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell. Oct 6 2006;127(1):125-37.

20. Zhang D, Facchinetti V, Wang X, Huang Q, Qin J, Su B. Identification of MEKK2/3 serine phosphorylation site targeted by the Toll-like receptor and stress pathways. EMBO J. Jan 11 2006;25(1):97-107.

21. Huang Q, Yang J, Lin Y, Walker C, Cheng J, Liu ZG, Su B. Differential regulation of interleukin 1 receptor and Toll-like receptor signaling by MEKK3. Nat Immunol. Jan 2004;5(1):98-103.

22. Yang J, Lin Y, Guo Z, Cheng J, Huang J, Deng L, Liao W, Chen Z, Liu Z, Su B. The essential role of MEKK3 in TNF-induced NF-kappaB activation. Nat Immunol. Jul 2001;2(7):620-4.

23. Yang J, Boerm M, McCarty M, Bucana C, Fidler IJ, Zhuang Y, Su B. Mekk3 is essential for early embryonic cardiovascular development. Nat Genet. Mar 2000;24(3):309-13.

24. Su B, Jacinto E, Hibi M, Kallunki T, Karin M, Ben-Neriah Y. JNK is involved in signal integration during costimulation of T lymphocytes. Cell. Jun 3 1994;77(5):727-36.

Patent

• “Screening for modulators of MEKK2 and MEKK3”, International Application Number: US2004040699W, International Publication Number: WO2005056825A1.

• “FK506或其可药用衍生物和铁死亡诱导剂联合在治疗癌症的药物中的用途”, Application Number: CN202210526646.8, Publication Number: CN114948951A.

• “一种小鼠肠道间质细胞亚群标记系统及其标记方法和应用”, Application Number: 2030CN-PJD2510139.

• “结直肠癌生物标志物及其在诊断、预防、治疗及预后中的应用”, Application Number: CN202010642872.3, Publication Number: CN113899903B.

• “结直肠癌肿瘤边界细胞亚群标志物组合及其应用”, Application Number: CN202211105843.9, Publication Number: CN116735874B.